wfh bangkok 2004 self-sufficiency of plasma derivatives

16
WFH Bangkok 2004 Self-Sufficiency of Plasma Derivatives

Upload: dorcas-andrews

Post on 17-Dec-2015

219 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: WFH Bangkok 2004 Self-Sufficiency of Plasma Derivatives

WFH Bangkok 2004

Self-Sufficiency of Plasma Derivatives

Page 2: WFH Bangkok 2004 Self-Sufficiency of Plasma Derivatives

WFH Bangkok 2004

Definition

The provision of human blood and plasma products from within a certain population to satisfy the clinical needs of that population

Page 3: WFH Bangkok 2004 Self-Sufficiency of Plasma Derivatives

WFH Bangkok 2004

History & Rationale

Council of Europe. Recommendation R (88) 4, March 1988 :

– Every country should aim at self-sufficiency in the supply and distribution of blood over its entire territory

– “ Self-sufficiency with respect to blood products is one of the basic conditions for minimising the hazard of the transmission of infectious disease by blood transfusion”

Page 4: WFH Bangkok 2004 Self-Sufficiency of Plasma Derivatives

WFH Bangkok 2004

Other Advantages

Improved utilisation of national resources Prevention of “virus tourism” Represents relevant local antibody content Cost reduction opportunity Increased availability of products Equality of treatment Avoids introduction of sub-optimal products

Page 5: WFH Bangkok 2004 Self-Sufficiency of Plasma Derivatives

WFH Bangkok 2004

Prerequisites

National commitment

Selection of a fractionation partner with experience in the development, administration and logistics of self-sufficiency projects

Page 6: WFH Bangkok 2004 Self-Sufficiency of Plasma Derivatives

WFH Bangkok 2004

Attaining Self-Sufficiency

Degree & cost-savings of self-sufficiency based on:

– Careful selection of fractionation partner– Safe & reliable project administration– Variable and small batch sizes– Safe, reliable and consistent production– State-of-the-art products– High yields

Page 7: WFH Bangkok 2004 Self-Sufficiency of Plasma Derivatives

WFH Bangkok 2004

Selection of Fractionation Partner

Proven experience of managing self-sufficiency projects

Fractionation capacity

International & local reputation

Solid financial background

Reliable local representation

Page 8: WFH Bangkok 2004 Self-Sufficiency of Plasma Derivatives

WFH Bangkok 2004

Safe & Reliable Project Administration Established history of self-sufficiency ability

“Total package” administration:– Donor centre auditing donor recruitment

programmes– Educational support staff training– Distribution transportation logistics

Trust & transparency

Pro-active problem-solving approach

Ongoing commitment to evaluation & improvement

Page 9: WFH Bangkok 2004 Self-Sufficiency of Plasma Derivatives

WFH Bangkok 2004

Variable Production Scales

Ability to offer both regional and national self-sufficiency requires:

– Production flexibility – Variable batch size – Short production & delivery schedules

Commitment to safety

Page 10: WFH Bangkok 2004 Self-Sufficiency of Plasma Derivatives

WFH Bangkok 2004

Safe, Reliable, Consistent Production

GMP: Good Manufacturing Practice

Batch-to-batch consistency

Attainment & maintenance of international standards – Independent batch release by recognised

international laboratories

Page 11: WFH Bangkok 2004 Self-Sufficiency of Plasma Derivatives

WFH Bangkok 2004

State-of-the-Art Products

Worldwide registrations

Double virus inactivation

Purification methods

Ongoing R&D programme

Product / portfolio enhancement option included in contract

Page 12: WFH Bangkok 2004 Self-Sufficiency of Plasma Derivatives

WFH Bangkok 2004

High Yields

Maximum utilisation of valuable national resource

Increased availability of products– More patients access treatment– Expansion of clinical indications – Improved treatment regimens

Prophylaxis Immune toleranceSurgical procedures

Optimised costs

Page 13: WFH Bangkok 2004 Self-Sufficiency of Plasma Derivatives

WFH Bangkok 2004

State-of-the-Art Facilities

Separation of product, material, personnel and waste flows

Validation of processes, analytical methods and equipment

Clean areas according to the production steps

Training of the employees

Efficient technology

Page 14: WFH Bangkok 2004 Self-Sufficiency of Plasma Derivatives

WFH Bangkok 2004

Dedicated to Self-Sufficiency

Size of the fractionation batches

Dedicated equipment according to plasma origin

Fractionation equipment with CIP and SIP

Autonomy for the whole process, from plasma to final product

Page 15: WFH Bangkok 2004 Self-Sufficiency of Plasma Derivatives

WFH Bangkok 2004

Octapharma & Self-Sufficiency

Octapharma products have significantly improved the quality of life for thousands of patients in Norway during the last 15 years

– Around 200 haemophiliacs are treated with Octapharma products every year

– Waiting-lists for elective surgery in haemophiliacs have disappeared

– The haemophilia treatment regimen has now reached a level of high European standard

– Emergency stock of plasma products increased from zero to six months

Flesland O et al. The Norwegian plasma fractionation project: A 12 year clinical & economic success story. Transfusion & Apheresis Science 2003; 28: 93-100

Page 16: WFH Bangkok 2004 Self-Sufficiency of Plasma Derivatives

WFH Bangkok 2004

Octapharma Self-Sufficiency Experience

More than 15 years experience with self-sufficiency programmes – Austria– Belgium– Brazil– Germany – Norway– Slovenia– France – Netherlands, etc